There are currently 459 clinical trials in Little Rock, Arkansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arkansas for Medical Sciences, Arkansas Children's Hospital, GSK Investigational Site and Arkansas Cancer Research Center at University of Arkansas for Medical Sciences. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
InSpace Accelerated Rehabilitation Study
NCT05329584
Recruiting
This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/22/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Rotator Cuff Tears
Register for Updates
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
NCT05101551
Recruiting
This is a Phase 1, open label, multicenter, dose finding study with dose expansion intended to evaluate the safety and tolerability of talazoparib in combination with conventional chemotherapy. Preliminary estimates of efficacy will be obtain through a dose expansion cohort receiving the maximum tolerated dose from the dose escalation phase of the study. This study aims to determine the safety of talazoparib in combination with conventional chemotherapy and to establish the maximum tolerated do... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/22/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Acute Myeloid Leukemia
Register for Updates
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
NCT05004129
Recruiting
This is an open-label phase 2/3 study for individuals with Congenital Myotonic Dystrophy (Congenital DM1) who participated in the preceding AMO-02-MD-2-003 study or individuals with either Congenital or Childhood Onset DM1 who are treatment naïve.
Gender:
ALL
Ages:
Between 6 years and 45 years
Trial Updated:
05/22/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Congenital Myotonic Dystrophy
Register for Updates
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552
Recruiting
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Hematological Malignancies
Register for Updates
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
05/21/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Langerhans Cell Histiocytosis
Register for Updates
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/21/2025
Locations: University of Arkansas for Medical Sciences-Site Number : 8400019, Little Rock, Arkansas
Conditions: Chronic Graft Versus Host Disease
Register for Updates
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
NCT06765668
Recruiting
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Parkinson Disease
Register for Updates
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
NCT02954094
Recruiting
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University of Arkansas, Little Rock, Arkansas
Conditions: Hepatocellular Cancer
Register for Updates
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044
Recruiting
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/20/2025
Locations: Vanda Investigational Site, Little Rock, Arkansas
Conditions: Major Depressive Disorder (MDD)
Register for Updates
Pompe Disease Registry Protocol
NCT00231400
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes. The objectives of the Registry are: * To enhance understanding of t... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/19/2025
Locations: Arkansas Childrens Hospital- Site Number : 840109, Little Rock, Arkansas +1 locations
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Register for Updates
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
NCT04696029
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
05/19/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Medulloblastoma
Register for Updates
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
NCT06540963
Recruiting
The purpose of this study is to evaluate the investigational drug, tipifarnib (a pill taken by mouth), in combination with the Food and Drug Administration (FDA) approved drug, naxitimab, administered intravenously (IV; a liquid that continuously goes into your body through a tube that has been placed during a surgery into one of your veins). Naxitamab is FDA approved for pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
05/19/2025
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Neuroblastoma Recurrent
Register for Updates